424 related articles for article (PubMed ID: 26191189)
1. Down-regulation of Rab17 promotes tumourigenic properties of hepatocellular carcinoma cells via Erk pathway.
Qi J; Zhao P; Li F; Guo Y; Cui H; Liu A; Mao H; Zhao Y; Zhang X
Int J Clin Exp Pathol; 2015; 8(5):4963-71. PubMed ID: 26191189
[TBL] [Abstract][Full Text] [Related]
2. Rab17 inhibits the tumourigenic properties of hepatocellular carcinomas via the Erk pathway.
Wang K; Mao Z; Liu L; Zhang R; Liang Q; Xiong Y; Yuan W; Wei L
Tumour Biol; 2015 Aug; 36(8):5815-24. PubMed ID: 25707355
[TBL] [Abstract][Full Text] [Related]
3. Vaccinia-related kinase 1 promotes hepatocellular carcinoma by controlling the levels of cell cycle regulators associated with G1/S transition.
Lee N; Kwon JH; Kim YB; Kim SH; Park SJ; Xu W; Jung HY; Kim KT; Wang HJ; Choi KY
Oncotarget; 2015 Oct; 6(30):30130-48. PubMed ID: 26375549
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
5. Matrine derivative WM130 inhibits hepatocellular carcinoma by suppressing EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways.
Qian L; Liu Y; Xu Y; Ji W; Wu Q; Liu Y; Gao Q; Su C
Cancer Lett; 2015 Nov; 368(1):126-134. PubMed ID: 26259512
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways.
Bao L; Yan Y; Xu C; Ji W; Shen S; Xu G; Zeng Y; Sun B; Qian H; Chen L; Wu M; Su C; Chen J
Cancer Lett; 2013 Sep; 337(2):226-36. PubMed ID: 23684551
[TBL] [Abstract][Full Text] [Related]
7. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
[TBL] [Abstract][Full Text] [Related]
8. The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration.
Chiu CY; Kuo KK; Kuo TL; Lee KT; Cheng KH
Mol Cancer Res; 2012 Mar; 10(3):415-27. PubMed ID: 22241220
[TBL] [Abstract][Full Text] [Related]
9. Suppression of ATAD2 inhibits hepatocellular carcinoma progression through activation of p53- and p38-mediated apoptotic signaling.
Lu WJ; Chua MS; So SK
Oncotarget; 2015 Dec; 6(39):41722-35. PubMed ID: 26497681
[TBL] [Abstract][Full Text] [Related]
10. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway.
Li T; Dong ZR; Guo ZY; Wang CH; Zhi XT; Zhou JW; Li DK; Chen ZT; Chen ZQ; Hu SY
Liver Int; 2015 Apr; 35(4):1416-29. PubMed ID: 25066210
[TBL] [Abstract][Full Text] [Related]
11. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
12. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
[TBL] [Abstract][Full Text] [Related]
13. Zic2 promotes tumor growth and metastasis via PAK4 in hepatocellular carcinoma.
Lu SX; Zhang CZ; Luo RZ; Wang CH; Liu LL; Fu J; Zhang L; Wang H; Xie D; Yun JP
Cancer Lett; 2017 Aug; 402():71-80. PubMed ID: 28577975
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
Liu Y; Sun L; Su X; Guo S
Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
[TBL] [Abstract][Full Text] [Related]
15. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.
Buurman R; Gürlevik E; Schäffer V; Eilers M; Sandbothe M; Kreipe H; Wilkens L; Schlegelberger B; Kühnel F; Skawran B
Gastroenterology; 2012 Sep; 143(3):811-820.e15. PubMed ID: 22641068
[TBL] [Abstract][Full Text] [Related]
17. Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth.
Wang Z; Wei W; Sun CK; Chua MS; So S
Liver Int; 2015 Apr; 35(4):1403-15. PubMed ID: 25098386
[TBL] [Abstract][Full Text] [Related]
18. Eukaryotic elongation factor-1α 2 knockdown inhibits hepatocarcinogenesis by suppressing PI3K/Akt/NF-κB signaling.
Qiu FN; Huang Y; Chen DY; Li F; Wu YA; Wu WB; Huang XL
World J Gastroenterol; 2016 Apr; 22(16):4226-37. PubMed ID: 27122673
[TBL] [Abstract][Full Text] [Related]
19. Neuroglobin, a novel intracellular hexa-coordinated globin, functions as a tumor suppressor in hepatocellular carcinoma via Raf/MAPK/Erk.
Zhang J; Lan SJ; Liu QR; Liu JM; Chen XQ
Mol Pharmacol; 2013 May; 83(5):1109-19. PubMed ID: 23478801
[TBL] [Abstract][Full Text] [Related]
20. MiR-3663-3p participates in the anti-hepatocellular carcinoma proliferation activity of baicalein by targeting SH3GL1 and negatively regulating EGFR/ERK/NF-κB signaling.
Tian J; Li J; Bie B; Sun J; Mu Y; Shi M; Zhang S; Kong G; Li Z; Guo Y
Toxicol Appl Pharmacol; 2021 Jun; 420():115522. PubMed ID: 33838155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]